Citations

Showing 10 of 108081 citations.

A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis
Lu, Calvin, Pappas, George P., Dilling, Daniel F. , Shifren, Adrian , Veeraraghavan, Srihari , Chapman, Jeffrey T., Parambil, Joseph G. , Ruoss, Stephen J. , Young, Lisa R. , Kopras, Elizabeth J. , Roads, Tammy, Krischer, Jeffrey P. , McCormack, Francis X. , McCormack, Francis X , Lu, Calvin, Lee, Hye Seung , Burger, Charles D. , Hammes, Stephen R.

Mayo Clinic

Annals of the American Thoracic Society | June 1, 2017 | Volume: 14 | Issue: 6 | Pages: 919-928

10.1513/annalsats.201610-824oc | PMID 28570161 Get It

Abstract Rationale Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease that predominantly affects women and can worsen with pregnancy, estrogen treatment, and the menstrual cycle, suggesting an important role for estrogen in disease pathogenesis. Objectives To assess the efficacy and safety of the aromatase inhibitor letrozole in the treatment of LAM. Methods Seventeen postmenopausal women with LAM were enrolled in this phase II trial and randomized to receive letrozole 2.5 mg daily (n = 9) or placebo (n = 8) for a period of 12 months. Five patients in each group were also taking sirolimus at baseline and remained on the drug throughout the treatment period. Lung function, exercise capacity, quality of life, and serum vascular endothelial growth factor D (VEGF-D) were measured at baseline and at 3-month intervals. Results Fifteen patients completed the study. Two patients withdrew. There were no differences in adverse events in the letrozole and placebo groups. The target enrollment of 25 patients per arm was not met, so the efficacy of letrozole could not be assessed as planned. After adjusting for sirolimus use, we found that the rate of change in FEV1 for all subjects was −3 ± 3 ml/mo (P = 0.4), and for serum VEGF-D, the rate of change was −0.024 ± 0.009 pg/ml/mo (P = 0.015), showing a steeper decline in the letrozole group (−0.029 ± 0.013; P = 0.025). All patients who were taking sirolimus had a reduction in VEGF-D levels from baseline to the last visit, compared with only half of the patients who were not taking sirolimus. In a post hoc analysis, eight matched letrozole-treated–placebo-treated pairs were constructed, six of which demonstrated better FEV1 improvement for the letrozole-treated patients. Conclusions Letrozole treatment appears to be safe and well tolerated in postmenopausal patients with LAM, including those taking sirolimus. Enrollment in this trial was compromised by the publication of an effective treatment (sirolimus) in the same month as the study opened, resulting in limited power to detect treatment effects. Post hoc matched pairs exploration studies provide tentative support for additional studies of letrozole in LAM. Considering the reduced rate of lung function decline in postmenopausal patients, future studies will likely require enhanced study designs, such as selective enrollment of those with prognostic biomarkers predictive of decline. Clinical trial registered with www.clinicaltrials.gov (NCT01353209).
Zinc deficiency primes the lung for ventilator-induced injury
Boudreault, Francis, Pinilla-Vera, Miguel , Englert, Joshua A. , Kho, Alvin T. , Isabelle, Colleen , Arciniegas, Antonio J. , Barragan-Bradford, Diana, Quintana, Carolina, Amador-Muñoz, Diana , Guan, Jiazhen, Choi, Kyoung Moo , Registry, MICU, Sholl, Lynette M. , Hurwitz, Shelley, Tschumperlin, Daniel J. , Baron, Rebecca M. , Registry, MICU

Mayo Clinic

JCI Insight | June 1, 2017 | Volume: 2 | Issue: 11 | Pages: No page available

10.1172/jci.insight.86507 | PMID 28570269 Get It

Mechanical ventilation is necessary to support patients with acute lung injury, but also exacerbates injury through mechanical stress–activated signaling pathways. We show that stretch applied to cultured human cells, and to mouse lungs in vivo, induces robust expression of metallothionein, a potent antioxidant and cytoprotective molecule critical for cellular zinc homeostasis. Furthermore, genetic deficiency of murine metallothionein genes exacerbated lung injury caused by high tidal volume mechanical ventilation, identifying an adaptive role for these genes in limiting lung injury. Stretch induction of metallothionein required zinc and the zinc-binding transcription factor MTF1. We further show that mouse dietary zinc deficiency potentiates ventilator-induced lung injury, and that plasma zinc levels are significantly reduced in human patients who go on to develop acute respiratory distress syndrome (ARDS) compared with healthy and non-ARDS intensive care unit (ICU) controls, as well as with other ICU patients without ARDS. Taken together, our findings identify a potentially novel adaptive response of the lung to stretch and a critical role for zinc in defining the lung’s tolerance for mechanical ventilation. These results demonstrate that failure of stretch-adaptive responses play an important role in exacerbating mechanical ventilator–induced lung injury, and identify zinc and metallothionein as targets for lung-protective interventions in patients requiring mechanical ventilation.
Effect of Obstructive Sleep Apnea Treatment on Lipids in Obese Children
Amini, Zarlasht, Kotagal, Suresh , Lohse, Christine M. , Lloyd, Robin M. , Sriram, Swetha, Kumar, Seema , Lohse, Christine, Lloyd, Robin, Kumar, Seema

Mayo Clinic

Children | June 1, 2017 | Volume: 4 | Issue: 6 | Pages: 44

10.3390/children4060044 | PMID 28587180 Get It

Obesity in children is associated with several co-morbidities including dyslipidemia. Obstructive sleep apnea (OSA) is commonly seen in obese children. In adults, diagnosis of OSA independent of obesity is associated with cardiometabolic risk factors including dyslipidemia. There is limited data on the impact of treatment of OSA on lipids in children. The objective of the study was to examine the impact of treatment of OSA on lipids in 24 obese children. Methods: Seventeen children were treated with continuous positive airway pressure (CPAP) and five underwent adenotonsillectomy. Mean apnea hypopnea index prior to treatment was 13.0 + 12.1 and mean body mass index (BMI) was 38.0 + 10.6 kg/m2. Results: Treatment of OSA was associated with improvement in total cholesterol (mean change = −11 mg/dL, p < 0.001), and low-density lipoprotein cholesterol (mean change = –8.8 mg/dL, p = 0.021). Conclusion: Obese children should be routinely screened for OSA, as treatment of OSA favorably influences lipids and therefore decreases their cardiovascular risk.
Technologies in pediatric vascular access: have we improved success rate in peripheral vein cannulation?
Haile, Dawit T. , Suominen, Pertti , Suominen, P K

Mayo Clinic

Acta Anaesthesiologica Scandinavica | June 1, 2017 | Volume: 61 | Issue: 7 | Pages: 710-713

10.1111/aas.12916 | PMID 28567816 Get It

Heart Rate and Rhythm Disorders
Wackel, Philip L. , Cannon, Bryan C. , Wackel, Philip, Cannon, Bryan

Mayo Clinic

Pediatrics In Review | June 1, 2017 | Volume: 38 | Issue: 6 | Pages: 243-253

10.1542/pir.2016-0119 | PMID 28572133 Get It

Is the Human Zygote a Person?
Nelson, Thomas K., Nelson, Thomas

Mayo Clinic

The Linacre Quarterly | June 1, 2017 | Volume: 72 | Issue: 4 | Pages: 281-293

10.1080/20508549.2005.11877761 | PMID 16471031 Get It

Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain
Swaminathan, Suresh Kumar, Ahlschwede, Kristen M. , Sarma, Vidur , Curran, Geoffry L., Omtri, Rajesh S. , Decklever, Teresa, Lowe, Val J. , Poduslo, Joseph F., Kandimalla, Karunya K. , Kandimalla, Karunya K

Mayo Clinic

Journal of Cerebral Blood Flow & Metabolism | June 1, 2017 | Volume: 38 | Issue: 5 | Pages: 904-918

10.1177/0271678x17709709 | PMID 28569090 Get It

Impaired brain clearance of amyloid-beta peptides (Aβ) 40 and 42 across the blood–brain barrier (BBB) is believed to be one of the pathways responsible for Alzheimer’s disease (AD) pathogenesis. Hyperinsulinemia prevalent in type II diabetes was shown to damage cerebral vasculature and increase Aβ accumulation in AD brain. However, there is no clarity on how aberrations in peripheral insulin levels affect Aβ accumulation in the brain. This study describes, for the first time, an intricate relation between plasma insulin and Aβ transport at the BBB. Upon peripheral insulin administration in wild-type mice: the plasma clearance of Aβ40 increased, but Aβ42 clearance reduced; the plasma-to-brain influx of Aβ40 increased, and that of Aβ42 reduced; and the clearance of intracerebrally injected Aβ40 decreased, whereas Aβ42 clearance increased. In hCMEC/D3 monolayers (in vitro BBB model) exposed to insulin, the luminal uptake and luminal-to-abluminal permeability of Aβ40 increased and that of Aβ42 reduced; the abluminal-to-luminal permeability of Aβ40 decreased, whereas Aβ42 permeability increased. Moreover, Aβ cellular trafficking machinery was altered. In summary, Aβ40 and Aβ42 demonstrated distinct distribution kinetics in plasma and brain compartments, and insulin differentially modulated their distribution. Cerebrovascular disease and metabolic disorders may disrupt this intricate homeostasis and aggravate AD pathology.
PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins
Pérez‐Soriano, Alexandra , Arena, Julieta , Dinelle, Katie , Miao, Qing , McKenzie, Jessamyn , Neilson, Nicole, Puschmann, Andreas , Schaffer, Paul , Shinotoh, Hitoshi , Smith‐Forrester, Jenna, Shahinfard, Elham , Vafai, Nasim, Wile, Daryl , Wszolek, Zbigniew, Higuchi, Makoto , Stoessl, A. Jon , Wszołek, Zbigniew K. , Sossi, Vesna , Puschmann, Andreas

Mayo Clinic

Movement Disorders | June 1, 2017 | Volume: 32 | Issue: 7 | Pages: 1016-1024

10.1002/mds.27029 | PMID 28568506 Get It

ABSTRACTBackground and Objectives: To study selective regional binding for tau pathology in vivo, using PET with [11C]PBB3 in PSP patients, and other conditions not typically associated with tauopathy.Methods: Dynamic PET scans were obtained for 70 minutes after the bolus injection of [11C]PBB3 in 5 PSP subjects, 1 subject with DCTN1 mutation and PSP phenotype, 3 asymptomatic SNCA duplication carriers, 1 MSA subject, and 6 healthy controls of similar age. Tissue reference Logan analysis was applied to each region of interest using a cerebellar white matter reference region.Results: In comparison to the control group, PSP subjects showed specific uptake of [11C]PBB3 in putamen, midbrain, GP, and SN. Longer disease duration and more advanced clinical severity were generally associated with higher tracer retention. A DCTN1/PSP phenotype case showed increased binding in putamen, parietal lobe, and GP. In SNCA duplication carriers, there was a significant increase of [11C] PBB3 binding in GP, putamen, thalamus, ventral striatum, SN, and pedunculopontine nucleus. The MSA case showed increased binding in frontal lobe, GP, midbrain, parietal lobe, putamen, temporal lobe, SN, thalamus, and ventral striatum.Conclusions: All PSP patients showed increased retention of the tracer in the basal ganglia, as expected. Binding was also present in asymptomatic SNCA duplication carriers and in an MSA case, which are not typically associated with pathological tau deposition. This suggests the possibility that [11C]PBB3 binds to alpha‐synuclein. © 2017 International Parkinson and Movement Disorder Society
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma
Ghosh, Toshi, Gonsalves, Wilson I. , Jevremović, Dragan , Dingli, David , Timm, Michael, Morice, William G. , Kapoor, Prashant , Kourelis, Taxiarchis , Lacy, Martha Q. , Hayman, Suzanne R. , Lin, Yi , Russell, Stephen J. , Lust, John A., Zeldenrust, Steven R., Warsame, Rahma , Hwa, Yi L. , Kyle, Robert A. , Kumar, Shaji , Timm, Michael M, Kourelis, Taxiarchis V, Buadi, Francis K. , Leung, Nelson , Go, Ronald S , Warsame, Rahma , Dispenzieri, Angela , Morice, William George , Leung, Nelson , Go, Ronald S. , Gertz, Morie A. , Rajkumar, S. Vincent , Gonsalves, Wilson , Russell, Stephen J , Jevremovic, Dragan , Dingli, David , Lin, Yi

Mayo Clinic

American Journal of Hematology | June 1, 2017 | Volume: 92 | Issue: 9 | Pages: No page available

10.1002/ajh.24807 | PMID 28568244 Get It

AbstractPrior studies have revealed that the presence of increasing number of polyclonal plasma cells (pPCs) in the bone marrow (BM) are associated with better outcomes in newly diagnosed multiple myeloma (MM) patients. This effect has not been studied in patients with MM at the time of disease relapse. We determined the prognostic value of depletion of pPCs in the BM by 7‐color multiparameter flow cytometry in a series of 174 relapsing MM patients. The time to next therapy (TTNT) in those with <5% pPCs was 9.4 months versus 13.9 months in those with ≥5% pPCs (P = .0091). The median overall survival (OS) in those with <5% pPCs was 21.4 months, while the median OS was not reached in those patients with ≥5% pPCs (P = .019). Of the 109 patients with standard risk cytogenetics, the median OS of those with <5% pPCs was 28.4 months, while the median OS was not reached in those with ≥5% pPCs (P = .033). As such, <5% pPCs in the BM appears to have prognostic utility in identifying a subset of relapsing MM patients, even with standard‐risk cytogenetics, who have a particularly adverse outcome.
A follow‐up on desiderosmia (olfactory craving), a novel symptom associated with iron deficiency anemia
Hansen, Bryar R. , Bottner, Wayne A., Ravindran, Aishwarya , DeJesus, Ramona S. , Go, Ronald S. , DeJesus, Ramona, Go, Ronald S , Ravindran, Aishwarya

Mayo Clinic

American Journal of Hematology | June 1, 2017 | Volume: 92 | Issue: 9 | Pages: No page available

10.1002/ajh.24806 | PMID 28568111 Get It